slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 74,431-74,460
Pages 3,679
Rows per page 30
Component
74,431-74,460 of 110,355
15
The slide uses a process flow for the utility side and a stakeholder/financing flow for the developer side.Eos Energy | Results Presentation Deck | 19 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · Action1 hit
16
The slide uses a funnel-like progression from lead generation to backlog.Eos Energy | Results Presentation Deck | 19 slides · Eos Energy Enterprises
Conference presentation Investor relations Beat · Action1 hit
06
Includes specific financial breakdown of deal value and R&D funding obligations.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Solution1 hit
17
The slide uses a four-column structure to explain the target, the molecule, the preclinical results, and the clinical results.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
18
The slide uses a column-based layout to compare four distinct disease indications.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Market Size1 hit
19
The slide uses Western blot data to visually demonstrate the efficacy of EQ101 compared to a standard JAK inhibitor.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
20
Includes before/after clinical photos and a comparative table against Mogamulizumab.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Beat · Traction1 hit
22
The slide uses a circular process diagram to show the feedback loop of immune cells and cytokines attacking the hair follicle.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
25
Includes a specific callout for a Blackbox warning on existing competitors.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
Includes a timeline-style process diagram for the study phases.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
29
Equillium | Investor Presentation Deck | 39 slidesEquillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
30
Includes a biological process diagram and a gene expression heatmap.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
31
The slide uses a biological pathway diagram and a bar chart to demonstrate efficacy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
32
The slide uses a process-like diagram to show treatment approaches and highlights the specific mechanism of action (IL-15/IL-21 inhibition) as a superior strategy.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
33
The slide outlines a sequential clinical trial process.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
38
The slide uses a grouped list format to present clinical trial milestones.Equillium | Investor Presentation Deck | 39 slides · Equillium
Pitch deck Investor relations 1 hit
03
The slide uses a hub-and-spoke diagram to connect the company name to three core pillars: leadership, portfolio, and financials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Introduction to Erasca and RAS/MAPK pathway1 hit
09
The slide uses a matrix structure to map indications to benchmarks, specific drug regimens, and trial names, with a footer detailing active clinical trial collaboration and supply agreements (CTCSAs).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
10
The chart uses a stacked bar approach to represent US and Europe patient counts per program, with a total sum at the bottom.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needsLoop · Logic Chain1 hit
12
The kinome tree is a standard visualization for kinase selectivity.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
13
The slide combines a biological pathway diagram with a clinical trial summary table to demonstrate proof of concept.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Challenges in current cancer treatment and unmet needs1 hit
16
Waterfall plot shows individual patient responses; table compares efficacy metrics against Dacarbazine and Binimetinib.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
17
The slide uses a before-after-framing approach to demonstrate clinical efficacy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
19
The slide uses a summary calculation (13/39 = 33.3% ORR) to aggregate results across two different clinical phases.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
20
Swimmer plot showing individual patient treatment duration and response status (NE, PD, PR, SD).Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical dataLoop · Cost Of Inaction1 hit
21
The diagram uses a flow-chart structure to categorize patient outcomes (off treatment vs on treatment) and further breaks down the 'on treatment' group into SDs and PRs with specific progression delay metrics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
30
Data cut 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
32
The slide highlights selectivity and potency, using arrows to indicate performance relative to the competitor.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
34
Includes RECIST 1.1 criteria reference and specific patient history.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit